Genzyme signals it may up AnorMED bid

Genzyme is displaying fresh signs that it won't give up on its bid to acquire AnorMED. AnorMED says that Genzyme has signaled its interest in upping its bid past the $12 a share offer from Millennium. And having triggered a bidding war, AnorMED has indicated that its interest now is in boosting shareholder value and notes that Millennium will have a chance to counter any sweetened offer made by Genzyme. Genzyme set off the bidding war with its offer to buy AnorMED for $8.55 a share, a move that was quickly spurned by AnorMED.

- here's the report on Genzyme from CBC

Related Articles
AnorMed rejects Genzyme takeover bid. Report
Genzyme to pursue rare hostile biotech bid. Report
Millennium to buy AnorMed for $515M. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.